Navigation Links
David Luci Joins MacroChem as General Counsel and Vice President Corporate Development
Date:12/6/2007

Luci Brings Successful Track Record of Building Value in Biotech Arena

Through Experience in Business Development and Investment Community

Outreach

WELLESLEY HILLS, Mass., Dec. 6 /PRNewswire-FirstCall/ -- MacroChem Corporation (OTC Bulletin Board: MACM) has appointed David P. Luci, Esq. as General Counsel and Vice President Corporate Development. Mr. Luci will also be Corporate Secretary with responsibilities encompassing all the company's legal matters including compliance with securities regulations and corporate governance. Included in the scope of Corporate Development activities will be responsibility for partnering activities and investor relations.

"I'm very pleased to welcome David to MacroChem. Having recently completed three very important milestones, we are confident that David's extensive experience will help bolster the company's continued momentum," stated Robert DeLuccia, President and CEO of MacroChem. "These key milestones are: last month's announcement of positive interim Phase 2 data for EcoNail(R) for the treatment of onychomycosis; the recent acquisition of exclusive worldwide license rights to pexiganan, a novel topical anti-infective peptide for the treatment of diabetic foot infection, which has already completed two Phase 3 trials; and the recent conversion of all preferred shares into common shares leaving only common stock, warrants, and options outstanding."

Most recently, Mr. Luci served as Executive Vice President and General Counsel of Bioenvision where he established the company's offices in New York, raised over $75 million in capital, and advanced Bioenvision stock listing from OTCBB to AMEX and then to NASDAQ. He was also responsible for garnering analyst interest for a number of investment firms. While at Bioenvision, he in-licensed the company's development-stage lead cancer drug for Japan and Southeast Asia and initiated drug development activities in Japan. He later successfully guided Bioenvision into a merger agreement and closing of a related tender offer with its U.S. co-development partner, Genzyme, in a transaction valued at approximately $345 million. Prior to joining Bioenvision, Mr. Luci practiced securities law and mergers and acquisitions at Paul, Hastings, Janofsky and Walker LLP, New York. Prior to PHJW, he was Senior Auditor, Ernst and Young, New York, focused on internal audit and controls within the Mergers and Acquisitions Practice Group. He is also a member of the Board of Directors and Chairman of the Audit Committee of Access Pharmaceuticals, Inc.

"David brings a diverse legal, financial, and business background as well as excellent knowledge of the biotech sector, both with pharmaceutical companies and the investment community of our industry," said Mr. DeLuccia. "His experience includes capital markets financing, negotiating deals, and license agreements (both U.S. and ex-U.S.), corporate partnerships, and mergers and acquisitions. I believe this impressive skill set will serve us well as we seek to capitalize on our recent achievements and advance our initiatives in the coming year."

Mr. Luci received his JD, cum laude, from Albany Law School of Union University, Albany, and his Bachelor of Science in Business Administration from Bucknell University. He is a member of the New York Bar Association and a Certified Public Accountant (Pennsylvania).

About MacroChem

MacroChem Corporation is a specialty pharmaceutical company that develops and seeks to commercialize pharmaceutical products. Our lead product candidate is EcoNail, a topically applied SEPA-based econazole lacquer for the treatment of onychomycosis, a condition commonly known as nail fungus. We recently acquired exclusive worldwide license rights to pexiganan, a novel topical anti-infective for the treatment of diabetic foot infection, which has already completed two Phase 3 trials. Our other clinical stage product candidate, Opterone(R), is a topically applied SEPA-based testosterone cream designed to treat male hypogonadism. Our pipeline of clinical-stage and early-stage product candidates is based on our SEPA, MacroDerm(TM) and DermaPass(TM) drug delivery technologies. For more information visit our website, http://www.macrochem.com.

Forward-Looking Statements

With the exception of historical information contained in this press release, the matters described herein are forward-looking statements that involve risks and uncertainties. MacroChem's actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed or referred to in the section entitled "Risk Factors" in MacroChem's Annual Report on Form 10-K, as well as those discussed elsewhere therein, and include, without limitation, risks regarding product development, the timing and results of clinical trials, the regulatory approval process, capital requirements, financial condition, patent protection and dependence on third parties for development and licensing arrangements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. MacroChem undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. For more information visit our website, http://www.macrochem.com.

Contact:

MacroChem: Bernard Patriacca - VP/CFO

(781) 489-7310

bpatriacca@macrochem.com

Investor Relations: The Investor Relations Group, Inc.

Christine Berni/ Joseph Triunfo, (212) 825-3210

cberni@investorrelationsgroup.com

jtriunfo@investorrelationsgroup.com

Media:

Bill Douglass/ Michaela Heller, (212) 825-3210

bdouglass@investorrelationsgroup.com

mheller@investorrelationsgroup.com


'/>"/>
SOURCE MacroChem Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. WorldHeart Appoints David Pellone Chief Financial Officer
2. Mylan Announces Appointment of David A. Lillback as Senior Vice President and Global Head of Human Resources
3. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
4. David Ward Joins OrthoSynetics(TM) as Western Region Sales Manager
5. The Law Offices of John David Hart: Texas Man Sues Medtronic in Body-Snatching Case
6. St. Davids Medical Center Implements New Robotic Technology to Treat Common Heart Rhythm Disorders
7. David Grimes, FHI physician, inducted into Institute of Medicine
8. David Kahal Joins AXA Equitable as National Sales Manager
9. Leading Authority on Health Benefits, David Hom, Joins Board of Directors of Healthcare Technology Innovator, NavigatorMD, Inc.
10. Tree named in honor of Virginia Tech chemist David G.I. Kingston
11. Richard Greco Joins Mediware Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ... that offers insurance and financial preparation services, is providing an update on a ... organization. , Rock City Rescue is a locally recognized nonprofit that provides shelter ...
(Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important ... problem. Fortunately, an inventor from Austin, Texas, has identified a solution. , She developed ... darkness or restricted lighting. As such, it eliminates the need to turn on a ...
(Date:10/13/2017)... IL (PRWEB) , ... October 13, 2017 , ... ... which established the certification process to promote standards of excellence for the field ... Symposium, scheduled for March 22 – 25, 2018 in Orlando, Florida at the ...
(Date:10/13/2017)... (PRWEB) , ... October 13, ... ... School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, ... professionals on guideline updates for the primary prevention of cardiovascular diseases during ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , ... mock evacuation of the facility as part of a disaster drill on October 3rd. ... EMS and Shelton City Emergency Manager, as well as the Connecticut Long Term ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)...  Eli Lilly and Company (NYSE: LLY ... quarter of 2017 on Tuesday, October 24, 2017. Lilly ... with the investment community and media to further detail ... will begin at 9 a.m. Eastern time. Investors, media ... of the conference call through a link that will ...
(Date:9/28/2017)... Sept. 28, 2017 Cohen Veterans Bioscience and ... use of wearable and home sensors for real-time monitoring ... Signal Foundation, a nonprofit organization focused on disruptive health ... an affordable analytical system to record and integrate behavioral, ... ...
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
Breaking Medicine Technology: